Insulin delivery technology developer Insulet (NSDQ:PODD) announced today that it appointed Dr. Luciana Borio to its board of directors.
Borio joins the board of Acton, Massachusetts–based Insulet, having served in key roles with the FDA, the National Security Council and the Council on Foreign Relations. She specializes in biodefense and medical countermeasures, emerging infectious diseases, medical product development, and public health emergencies.
“We are so pleased to welcome Dr. Borio to Insulet’s board,” Timothy Scannell, chair of Insulet’s board of directors, said in a news release. “Dr. Borio’s unique experience of working with government agencies on some of the world’s most complex public health challenges, along with her clinical and scientific expertise, and her passion for advancing public health, will be incredibly valuable to our Board as we continue to advance our growth strategy.”
She joined ARCH Venture Partners in July 2021 to advise on new investment opportunities related to biologics manufacturing, clinical trials, novel therapies and areas with large, unmet clinical needs. Before ARCH, Borio was SVP at In-Q-Tel and the medical and biodefense preparedness policy director at the National Security Council.
Before that, while at the FDA, Borio’s roles included acting chief scientist and assistant commissioner for counterterrorism policy, playing a part in developing and executing the FDA’s responses to the 2009 H1N1 flu pandemic, the 2014 Ebola epidemic and the 2015 Zika outbreak.
Most recently, Borio was a member of the President’s Transition COVID-19 Advisory Board. She continues to practice medicine at Johns Hopkins Hospital.
As Borio joins Insulet’s board, Sally W. Crawford will retire from her seat, effective on Dec. 31, 2021. She has offered 13 years of service to Insulet’s board.
“We thank Sally for her dedication, leadership, and guidance while serving on Insulet’s board,” Scannell said. “Sally has been a passionate advisor and a true friend to all of us. We are grateful for her immense contributions to Insulet and our mission to improve the lives of people with diabetes.”